Report by the ACNP Task Force on response and remission in major depressive disorder. - Wikidata - wikimedia - TriplyDB

Report by the ACNP Task Force on response and remission in major depressive disorder.

Report by the ACNP Task Force on response and remission in major depressive disorder.

http://www.wikidata.org/entity/Q36516394

about

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes Personalized medicine in major depressive disorder -- opportunities and pitfalls Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).Agomelatine: The evidence for its place in the treatment of depression Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials The depression treatment cascade in primary care: a public health perspective.Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults Music in depression: Neural correlates of emotional experience in remitted depression How emotional abilities modulate the influence of early life stress on hippocampal functioning.Using daily monitoring of psychiatric symptoms to evaluate hospital length of stay.Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antide DHA serum levels were significantly higher in celiac disease patients compared to healthy controls and were unrelated to depression.Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.The Impact of Residual Symptoms in Major Depression Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.Antidepressant pharmacotherapy in adults with type 2 diabetes: rates and predictors of initial response Defining recovery from an eating disorder: Conceptualization, validation, and examination of psychosocial functioning and psychiatric comorbidity Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.Attachment and social adjustment: relationships to suicide attempt and major depressive episode in a prospective study Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression.Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial.Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency.A benefit-risk assessment of agomelatine in the treatment of major depression.Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials.Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials.Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo Internet-based treatment of major depression for patients on a waiting list for inpatient psychotherapy: protocol for a multi-centre randomised controlled trial.Natural course of cannabis use disorders.Pioglitazone could induce remission in major depression: a meta-analysis Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.Partial remission, residual symptoms, and relapse in depression.Remission in major depression: results from a geriatric primary care population.Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version.

P2860

Q21144599-7F7B4F1D-17FB-4979-A012-A7D9FA6FF1DC Q24170133-1FECCDF6-6A1A-4036-9DCC-AC7A3574751F Q24602982-4C6B3654-3A47-4A7F-B8EB-453C9C327467 Q24617019-A164E369-1A0A-4C3D-A3D6-DD1DD9739480 Q24646517-0070207B-E2C4-43C3-B533-E64F1E3AF2BA Q26752694-F0B15750-6908-4F2F-BC55-63A03FF7DAE3 Q26828452-52FC1872-C429-4884-82E8-C5BE92277007 Q27027184-85E5B5A4-A18B-48E4-A31B-D0A35973B7E0 Q27692061-FE475139-250D-47EB-945C-223238AE14EA Q28764080-9F7957CA-1006-49EF-B550-FB31263617C2 Q30355089-CFBB2E77-25B6-4C2F-91A9-89D217EA6E1B Q30408079-F1419C19-004D-41E7-AC93-A080081A74B9 Q30490331-2A9E2BD0-BBA2-44B6-B642-7101B34F765A Q31061376-7F060150-2AF5-4B83-9EDF-8D19135435F4 Q33632801-C28C55A0-AB24-4C0C-ADB5-2083BD1805AF Q33655082-CA74D1B0-6C0A-4732-9832-46D6F464FCEC Q33664080-4645B550-8C41-48BE-AE30-D63B47F60FF3 Q33667966-1B2F3122-A502-46A2-B084-EEA435445CA0 Q33683586-44F342D7-0A32-4B08-AD82-F2336EDC7CE6 Q33691346-A7435A32-64F9-455E-9860-C6A6E375D63E Q33730306-0A123CCB-0E96-48DA-B159-754326A24D75 Q33745342-309EC83B-C625-4396-9F29-66BBB0A1CD13 Q33782206-36991725-2AFC-4784-8756-8C01C19C028F Q33812060-20D22264-D2A2-4DA1-8117-0465401DD5E0 Q33857182-CA059D3D-9194-4A2E-A847-9ED97A4A173A Q33900047-2B0927E0-0E21-4CF1-87A1-ACBBA1E05407 Q33900246-CEA63A3B-CC71-4E98-ABEA-DC62D818AA04 Q33955258-1546A4ED-D399-4437-AD5E-C0BA84701881 Q34207131-4EA59556-DC15-47E3-8688-2B63ED88BAE5 Q34315319-242554E2-733C-4213-A4BE-36B84244EECD Q34324317-36CDA416-A7ED-434E-BBBE-367DE82A1714 Q34333771-7A8E7061-33B2-494F-8DEE-866E01AD01ED Q34378212-F2A177C0-0AF1-402B-97E6-CF42B958AC60 Q34465439-8227140F-B621-4B24-8CE8-A9B6DF3B703B Q34498865-ECAE6219-5BDC-493C-9524-180020F246B4 Q34548227-B74A4080-1A45-4102-8C42-AC970CDFFFB2 Q34572593-8FC79B9A-6A57-4CD1-B4C0-E69F164FDD1B Q34603620-CFDEE1D8-85A9-4DE0-BC8E-DC0BEAA7105E Q34626301-2EEFF538-E3C0-4C3D-A4CF-E2A03337FE6C Q34626306-6C101A88-6B08-4619-94C4-8BC187FB0BFE

P2860

Report by the ACNP Task Force on response and remission in major depressive disorder.

http://www.wikidata.org/entity/Q36516394

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Report by the ACNP Task Force on response and remission in major depressive disorder.

@ast

Report by the ACNP Task Force on response and remission in major depressive disorder.

@en

type

label

Report by the ACNP Task Force on response and remission in major depressive disorder.

@ast

Report by the ACNP Task Force on response and remission in major depressive disorder.

@en

prefLabel

Report by the ACNP Task Force on response and remission in major depressive disorder.

@ast

Report by the ACNP Task Force on response and remission in major depressive disorder.

@en

P1433

Q36516394-D728A5D3-8D29-433C-8469-D467BB9056FD

P1476

Q36516394-2839B7AF-E045-4130-9E55-A25553149DFA

P2093

Q36516394-1D1C2E16-12E9-4A03-8B78-9B04C09A8207

Q36516394-24263472-F0D3-4084-A346-73DB07E2D34F

Q36516394-4D963F40-FC62-4D60-8F4E-B8750DB5E996

Q36516394-5771CD57-1EE3-4075-A77B-5DF7D4547CCA

Q36516394-676773AC-D6B8-4DAE-A5B5-3821E1391A73

Q36516394-7FA06175-9354-4EE1-A3A7-F38435390758

Q36516394-84C6E4C7-712B-4E1B-AB75-06CA489300D8

Q36516394-A441421D-F02A-41E7-96E4-8C9E3F167247

Q36516394-A7DC281F-B64D-4A3B-8586-EDD1A4DF4116

Q36516394-B7CB8322-AD63-408C-8FA0-8C702A9F80EB

P2860

Q36516394-331BFEB4-8917-4C47-A1C7-C03F90359CB3

Q36516394-50087C39-F316-45DB-A591-BDF1F6FBAC8D

Q36516394-5AAA0457-FD5F-497E-80B9-F53EF021DE24

Q36516394-60D4942E-00CB-45FA-9F23-39580783FD3D

Q36516394-81EFC246-208A-480E-8E13-0BD0C1FAA138

Q36516394-899AE353-EDB0-4AE6-967B-85E9239566B5

Q36516394-9DCC0246-292D-43B1-AD74-606A2F937839

Q36516394-C0377749-D92C-4E93-8E7F-6ED33D022D87

Q36516394-D85FC842-077B-4120-88CD-7F78454BF18E

Q36516394-DBA35F06-8934-4118-B141-5D98579951E4

P2888

Q36516394-13FF1D4A-E310-417B-BF82-0BD7A99F8388

P304

Q36516394-C653976C-9B66-41C1-854F-49E1AFF79E78

P31

Q36516394-FD750244-2762-469E-8B26-9B2510E46F48

P356

Q36516394-33F66EF0-7198-4BEF-8364-33DA7E786CF6

P407

Q36516394-941FBDBB-7117-4B55-BAB6-63FF23D80F26

P433

Q36516394-7E309FCC-6B63-45E8-8BEE-47E59A72F82F

P478

Q36516394-26B9265B-1E1A-4A40-AD98-407B2788DE5E

P50

Q36516394-10682C09-4526-4D55-AA31-246F49430BBC

Q36516394-B577D57A-8A20-44BF-9F73-E6459BA1A754

P577

Q36516394-DD9AB264-B56D-48EB-B782-F40548DA235B

P5875

Q36516394-07884119-A6BB-4B45-9451-5EF95C28030C

P698

Q36516394-F7FD5D89-0234-4CF0-935F-29EDF20DB956

P356

P1433

Neuropsychopharmacology

P1476

Report by the ACNP Task Force on response and remission in major depressive disorder.

@en

P2093

A John Rush

http://www.w3.org/2001/XMLSchema#string

ACNP Task Force

http://www.w3.org/2001/XMLSchema#string

Alan F Schatzberg

http://www.w3.org/2001/XMLSchema#string

Alan J Gelenberg

http://www.w3.org/2001/XMLSchema#string

Darrel A Regier

http://www.w3.org/2001/XMLSchema#string

David J Kupfer

http://www.w3.org/2001/XMLSchema#string

Ellen Frank

http://www.w3.org/2001/XMLSchema#string

Harold A Sackeim

http://www.w3.org/2001/XMLSchema#string

Jerrold F Rosenbaum

http://www.w3.org/2001/XMLSchema#string

Madhukar H Trivedi

http://www.w3.org/2001/XMLSchema#string

P2860

An Inventory for Measuring Depression

Development of a rating scale for primary depressive illness

The number needed to treat: a clinically useful measure of treatment effect

12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression).

Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.

Continuation drug therapy for major depressive episodes: how long should it be maintained?

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Treatments of depression and the functional capacity to work.

Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

P2888

P304

1841-1853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1301131

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Helena Chmura Kraemer

P577

2006-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6989098

http://www.w3.org/2001/XMLSchema#string

P698

16794566

http://www.w3.org/2001/XMLSchema#string